Amarillo Biosciences (AMAR) Stock Price, News & Analysis

Company Overview

Amarillo Biosciences, Inc., a healthcare company, engages in the discovery and development of pharmaceutical and biotech products in the United States and Asia. The company operates in three divisions: Pharmaceutical, Medical, and Consumer. The Pharmaceutical division offers low-dose non-injectable interferon (IFN) for the treatment of neoplastic, viral, and fibrotic diseases. The Medical division focuses on medical devices and developing technology to treat metabolism related diseases, such as Type 1 and Type 2 diabetes. The Consumer division provides a range of nutraceutical and food supplement products that utilize a liposomal delivery system. It owns four issued patents related to the low-dose oral delivery of interferon; one patent is for a product promoting oral health; and three patents are associated with treatment of metabolic disorders. The company was incorporated in 1984 and is based in Amarillo, Texas.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 6,100 shs
• Average Volume: 18,253 shs
• Market Capitalization: $25.24 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

AMAR Stock Analysis - Frequently Asked Questions

How were Amarillo Biosciences' earnings last quarter?

Amarillo Biosciences, Inc. (OTCMKTS:AMAR) announced its quarterly earnings results on Wednesday, November, 14th. The company reported ($0.01) earnings per share (EPS) for the quarter. The company earned $0.02 million during the quarter.

How do I buy shares of Amarillo Biosciences?

Shares of AMAR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Amarillo Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Amarillo Biosciences investors own include Fulcrum Therapeutics (FULC), Cerecor (CERC), Neos Therapeutics (NEOS), VIVUS (VVUS), AquaBounty Technologies (AQB), Astria Therapeutics (ATXS) and CymaBay Therapeutics (CBAY).

Company Calendar

• Last Earnings: 11/14/2018
• Today: 5/14/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:AMAR
• CIK: 1014763
• Web: www.amarbio.com
• Phone: 806-376-1741
• Fax: N/A
• Employees: 2
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-1,450,000.00
• Net Margins: -41,453.98%
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -574.29%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.03
• Quick Ratio: 0.07

Sales & Book Value

• Annual Sales: $20,000.00
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.03) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 42,066,000
• Free Float: N/A
• Market Cap: $25.24 million
• Optionable: Not Optionable
• Beta: -0.06